C4 therapeutics reports recent business highlights and second quarter 2021 financial results

– dosed first patient in phase 1/2 clinical trial of cft7455, a novel ikzf1/3 degrader, in hematologic malignancies; data expected in 2022 –
CCCC Ratings Summary
CCCC Quant Ranking